Article
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer.
Cancer research - 15 Sept 2011
Yang Xuemei, Turke Alexa B, Qi Jie, Song Youngchul, Rexer Brent N, Miller Todd W, Jänne Pasi A, Arteaga Carlos L, Cantley Lewis C, Engelman Jeffrey A, Asara John M
Abstract excerpt
Phosphatiditylinositide-3-kinase (PI3K) is activated in some cancers by direct mutation, but it is activated more commonly in cancer by mutation of upstream acting receptor tyrosine kinases (TK). At present, there is no systematic method to determine which TK signaling cascades activate PI3K in certain cancers, despite the likely utility of such information to help guide selection of tyrosine kinase inhibitor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.